Magnus Dahlbom
Overview
Explore the profile of Magnus Dahlbom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ells Z, Ludwig V, Weiner A, Kimura K, Farolfi A, Chamie K, et al.
Methods
. 2025 Feb;
236:10-16.
PMID: 39988309
Introduction: Surgeons commonly use cross sectional images to plan and prepare for surgical procedures. However, cognitively translating 2D images to surgical settings can be difficult and lead to sub-optimal resections....
2.
Yu R, Gardner L, Ells Z, Dahlbom M, Salavati A, Bahri S
AACE Clin Case Rep
. 2025 Feb;
11(1):75-76.
PMID: 39896945
No abstract available.
3.
Weiner A, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, et al.
Eur Urol Open Sci
. 2024 Nov;
70:36-42.
PMID: 39483519
Background And Objective: Prostate-specific membrane antigen (PSMA) radioguided salvage pelvic lymph node dissection (S-PLND) has emerged as a feasible treatment option for prostate cancer recurrence following initial surgery. This study...
4.
Hotta M, Kim G, Rerkpichaisuth V, Teng P, Armstrong W, Carlucci G, et al.
J Nucl Med
. 2024 Oct;
65(11):1789-1794.
PMID: 39362770
Recent studies have demonstrated promising results of fibroblast activation protein (FAP) inhibitor (FAPI) PET in prognosticating and monitoring interstitial lung diseases (ILDs). As a first step toward successful translation, our...
5.
Ells Z, Grogan T, Czernin J, Dahlbom M, Calais J
J Nucl Med
. 2024 Jul;
65(8):1264-1271.
PMID: 38960712
Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of Lu make it one of...
6.
Mellhammar E, Dahlbom M, Vilhelmsson-Timmermand O, Strand S
J Nucl Med
. 2023 Nov;
64(10):1632-1637.
PMID: 37934033
In radiopharmaceutical therapy, intratumoral uptake of radioactivity usually leads to heterogeneous absorbed dose distribution. The likelihood of treatment success can be estimated with the tumor control probability (TCP), which requires...
7.
Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, et al.
J Nucl Med
. 2023 Oct;
64(11):1772-1778.
PMID: 37797974
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising option for metastatic castration-resistant prostate cancer. Clinical experience using Lu or Ac has demonstrated encouraging treatment responses; however, responses are...
8.
Ma T, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, et al.
BJU Int
. 2023 Feb;
132(1):65-74.
PMID: 36797449
Objective: To assess the efficacy of Lu-PNT2002, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in combination with stereotactic body radiotherapy (SBRT) to...
9.
Hope T, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald L, et al.
J Nucl Med
. 2023 Feb;
64(2):204-210.
PMID: 36725249
No abstract available.
10.
Colbert C, Hollowed J, Nguyen D, Duarte-Vogel S, Dahlbom M, Hu P, et al.
Magn Reson Med
. 2022 Nov;
89(4):1557-1566.
PMID: 36382769
Purpose: To investigate model-fitted fractional myocardial blood volume (fMBV) derived from ferumoxytol-enhanced MRI as a measure of myocardial tissue hypoperfusion at rest. Methods: We artificially induced moderate to severe focal...